In patients with early-stage EGFR-mutant NSCLC, the ADAURA trial (NCT02511106) demonstrated that adjuvant osimertinib significantly improved both OS and PFS following complete resection[20,21]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.